1. Meaning 

The Commercial Genome Accountability Governance Doctrine is a proposed legal and regulatory framework for ensuring that businesses using human genetic information remain accountable for how they collect, analyze, store, share, license, research, and monetize genomic data.

Genomic data includes information derived from DNA sequencing, genetic variants, inherited characteristics, disease predispositions, and biological relationships. Commercial applications include genetic diagnostic services, pharmaceutical research, personalized medicine, ancestry testing, biotechnology patents, and genomic artificial intelligence.

Important legal clarification: The term Commercial Genome Accountability Governance Doctrine is not, as such, a universally recognized or formally established legal doctrine. It is an analytical framework derived from existing principles of privacy, informed consent, medical confidentiality, data protection, intellectual property, consumer protection, and corporate responsibility.

In India, an important constitutional foundation is Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), in which the Supreme Court recognized privacy as a fundamental right, including protection of personal information and individual autonomy.

Indian Kanoon

The central question is:

When a company earns commercial value from human genomic information, what legal duties does it owe to the individuals whose biological information makes that business possible?

The doctrine addresses this question through six interconnected principles:

Consent: Individuals should understand the proposed collection and use of their genetic data.

Privacy: Genomic information must receive appropriate protection against unauthorized disclosure and misuse.

Transparency: Commercial purposes, data recipients, and material risks should be disclosed.

Accountability: Organizations must be able to demonstrate compliance and answer for unlawful conduct.

Fairness: Genetic information should not become a basis for unjustified discrimination or exploitation.

Remedies: Individuals should have meaningful avenues for complaints, correction where appropriate, compensation where legally available, and regulatory intervention.

2. Why commercial genome governance is necessary

Genetic Algorithms: From Theory to Application · SWAYAM Plus

A. Genetic information is unusually sensitive

Genomic information can reveal inherited disease risks, biological relationships, and information about relatives who never directly provided a sample. Unlike a password, a person's underlying genome cannot simply be changed following a data breach.

Advanced Precision Medicine Laboratory - Research Services - The Jackson Laboratory

B. Commercial value can exceed the original purpose

A sample initially collected for diagnosis may later support drug development, algorithm training, biomarker discovery, or licensing. Governance must address whether those later uses fall within the original consent and applicable law.

Laboratory Informatics Industry Rising Backed by United States

C. Responsibility may be fragmented

Hospitals, laboratories, sequencing providers, cloud-storage companies, pharmaceutical firms, and research institutions may each control part of the process. Contracts cannot automatically eliminate an organization's own legal duties.

These risks make it necessary to assess not only whether genomic research is scientifically useful, but also whether the commercial process respects autonomy, privacy, safety, and lawful data use.

3. Principal legal principles

A. Informed consent and purpose limitation

Consent should not be treated as a blank cheque authorizing every future commercial use of a person's genome.

A responsible genomic service should explain, as applicable:

Whether the sample will be sequenced and which categories of data will be generated.

Whether the data will be used for research, product development, or commercial licensing.

Whether third-party laboratories, pharmaceutical companies, or researchers will receive access.

Whether the data will be identifiable, pseudonymized, or aggregated.

Whether future uses may reveal unexpected health or family information.

What withdrawal of consent can and cannot accomplish once data has been incorporated into research or derived products.

The precise consent requirements depend on the applicable statute, research rules, contractual relationship, and clinical context.

B. Privacy and confidentiality

Genetic data should be protected through proportionate security measures, access restrictions, encryption, controlled sharing, and procedures for responding to breaches.

Pseudonymization does not guarantee anonymity. Genomic information may sometimes be linked back to an individual through other available information.

C. Corporate accountability

A company should be able to demonstrate that it has a lawful basis for processing data and has implemented suitable governance. This includes documented decisions, staff responsibilities, vendor oversight, security controls, complaint handling, and appropriate retention and deletion procedures.

D. Non-discrimination and fairness

Commercial organizations should not use genetic predictions to impose unjustified disadvantages in employment, insurance, lending, healthcare access, or other important decisions. The legal prohibition and available remedies depend on the jurisdiction and the specific activity.

E. Commercial benefit and ownership

Three separate questions must be distinguished:

Who controls the physical biological sample?

Who may lawfully process the genomic information?

Who owns or may exploit a patentable invention or commercially developed product?

Permission to analyze a sample does not automatically answer the other two questions. Likewise, a patent on a qualifying invention does not automatically confer ownership of the donor's identity or unrestricted rights to exploit the donor's personal information.

4. Leading case laws

The following judgments establish important components of the proposed framework. They do not collectively establish a single, formally named Commercial Genome Accountability Governance Doctrine.

1. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1

Indian Supreme Court

Facts and issue: The Supreme Court considered whether the Constitution protects a fundamental right to privacy.

Decision: The nine-judge bench recognized privacy as a constitutionally protected fundamental right, grounded in liberty, dignity, and personal autonomy. Informational privacy forms an important part of this protection.

Indian Kanoon

Application to commercial genomics: A company's handling of identifiable genetic information can implicate privacy and autonomy. In the private-sector setting, the judgment supplies a constitutional foundation, while the specific legal claim and remedy depend on the applicable legislation and circumstances.

Governance principle: Genomic processing should be lawful, transparent, proportionate where the relevant legal test applies, and respectful of individual autonomy.

2. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

Facts: A patient consented to a diagnostic procedure, but the doctor performed additional, more extensive surgery without obtaining the specific consent ordinarily required.

Decision: The Supreme Court explained the requirements of valid medical consent and the circumstances in which additional procedures may be justified by an emergency.

Application: If a diagnostic laboratory or healthcare provider uses a patient's genetic sample for an additional commercial research purpose, the original consent cannot automatically be assumed to authorize that purpose. Whether fresh consent is legally necessary depends on the nature of the use and the applicable rules.

Governance principle: Obtain valid consent, disclose material information, and document the scope of authorization.

Indian Kanoon

3. Moore v. Regents of the University of California, 51 Cal. 3d 120 (1990)

US precedent

Facts: John Moore alleged that his physician failed to disclose research and economic interests relating to cells removed during medical treatment. Those cells were subsequently used to develop a commercially valuable cell line.

Decision: The California Supreme Court held that the allegations could support claims based on breach of fiduciary duty and lack of informed consent, but rejected the conversion claim concerning the removed cells.

California Supreme Court Resources+1

Application: Commercial research using human biological material raises questions about disclosure, professional conflicts, and informed consent. The judgment does not establish a universal rule that donors own all resulting products or are automatically entitled to commercial profits.

Governance principle: Disclose material financial and research interests where legally required, and do not confuse consent rights with ownership rights.

4. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

Facts: Myriad Genetics identified the location and sequence of BRCA1 and BRCA2 genes associated with elevated cancer risk and obtained patents involving those genes.

Decision: The US Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated. Synthetically created complementary DNA (cDNA) may be patent-eligible, subject to the Court's reasoning and the applicable patent requirements.

LII / Legal Information Institute

Application: Commercial genomic businesses cannot equate discovering a naturally occurring human gene with creating a patentable invention. The eligibility of particular diagnostic methods, engineered sequences, and other inventions must be assessed separately.

Governance principle: Patent claims should respect applicable limits on monopolizing natural genetic information.

5. S. and Marper v. United Kingdom, Applications Nos. 30562/04 and 30566/04 (2008)

Legal issue: The retention of fingerprints and DNA samples or profiles from individuals whose criminal proceedings had ended without conviction.

Decision: The European Court of Human Rights found a violation of Article 8 of the European Convention on Human Rights in the circumstances of the case, emphasizing the sensitive character of DNA information and the privacy implications of its indefinite retention.

Application: Retaining genomic data can itself create privacy risks, even when the information is not immediately disclosed or used against the individual. This is a human-rights judgment concerning state retention, not a direct ruling on private genomic businesses.

Governance principle: Retention periods should have a defensible legal basis and be no longer than justified by the applicable purpose and law. The Indian Supreme Court's privacy judgment discusses comparable concerns about genetic information.

Indian Kanoon

6. Abhishek Paruthi v. The State (NCT of Delhi), 2023

Legal issue: The use of DNA testing in legal proceedings and the need to balance evidentiary objectives with privacy.

Significance: The judgment discusses the unique and sensitive nature of DNA, including its capacity to reveal identity, family relationships, and health-related information, and refers to proportionality under the privacy jurisprudence.

Indian Kanoon

Application: The decision supports careful scrutiny of intrusive genetic testing and demonstrates why genetic information should not be treated as ordinary business data.

Governance principle: Genetic collection and use should be justified by a legitimate purpose and appropriate safeguards.

5. Indian statutory framework

Commercial genome governance in India is shaped by several overlapping legal regimes rather than a single genome-specific accountability statute.

Digital Personal Data Protection Act and Rules

The Digital Personal Data Protection Rules, 2025 were notified on 14 November 2025. The framework addresses consent, transparency, purpose limitation, data minimization, security safeguards, and accountability.

Press Information Bureau+1

An important qualification is that commencement is phased. As of 2 November 2026, the Act's substantive processing obligations and individual-rights provisions are not all yet in force; the official commencement schedule provides an 18-month period from the November 2025 notification for many of those provisions. Businesses must check the provisions already in force, the applicable transition dates, and any other laws that apply to their activities.

MeitY+1

The Act does not create a separate, comprehensive ownership regime for human genomes. Nor should genomic data automatically be assumed to fall under a special statutory category merely because it is scientifically sensitive; the precise legal treatment must be assessed under the applicable provisions.

Patent law

Under Indian patent law, an invention must satisfy the statutory requirements for patentability and must not fall within an applicable exclusion. Section 3(c) of the Patents Act addresses the discovery of a scientific principle or the formulation of an abstract theory, while section 3(j) excludes specified plants and animals, including parts thereof, subject to the statutory wording.

The US Supreme Court's Myriad Genetics decision is persuasive comparative material, not binding Indian patent law. Indian patentability must be decided under the Indian statute and relevant Indian authorities.

6. Accountability and governance mechanisms

A commercial genomics organization can translate the proposed doctrine into an operational compliance framework.

1. Consent and authorization register

Record the purpose for collection, permissions obtained, material disclosures, approved research uses, and any applicable withdrawal or objection requests.

2. Data protection and security

Use role-based access, encryption, audit logs, vendor assessments, incident-response procedures, and appropriate deletion or retention controls.

3. Commercial-use review

Before licensing datasets, training AI models, or sharing data with pharmaceutical companies, verify legal authority, consent scope, contractual restrictions, and re-identification risks.

4. Independent oversight

Assign responsibility to appropriate privacy, legal, security, and research-ethics personnel. Escalate high-risk projects and investigate suspected misuse.

5. Complaints and remedies

Provide an accessible complaint process, investigate incidents, preserve evidence, notify affected parties or authorities where required, and provide legally available remedies.

These mechanisms are proposed governance practices. Which controls are mandatory depends on the organization's activities, the laws in force, and the applicable research or clinical standards.

7. Illustrative legal problems

Scenario A: A genetic testing company sells customer data

A company collects DNA samples for ancestry reports. Its terms of service do not clearly explain that identifiable genetic information may later be licensed to a pharmaceutical company.

Legal analysis:

Was there valid authorization for the secondary use?

Were the commercial purpose and relevant recipients disclosed as required?

Did the company comply with applicable privacy, contractual, and research requirements?

Did the transfer create additional risks for the customer or their relatives?

The mere fact that the customer paid for a test does not automatically authorize every subsequent commercial use.

Scenario B: A researcher develops a profitable diagnostic invention

A laboratory uses properly obtained samples to identify a clinically valuable genetic marker and develops a diagnostic product.

Legal analysis:

The researcher or company may be able to obtain patent protection if the invention qualifies under the applicable law. However, patent eligibility, permission to use the original samples, consent to data processing, confidentiality, and any contractual benefit-sharing obligations are separate issues.

Moore and Myriad Genetics illuminate different parts of this problem, but neither creates a universal rule that a genomic donor automatically owns the resulting invention or is entitled to a share of its profits.

Scenario C: A genomic database is breached

A commercial laboratory suffers a cyberattack, exposing genetic records and associated medical information.

Legal analysis:

The response should include containment, investigation, preservation of evidence, assessment of re-identification and family-related risks, and any notifications required by applicable law. Potential liability will depend on the organization's legal duties, the circumstances of the breach, causation, and the available statutory or civil remedies.

The sensitivity of genetic information is an important reason to adopt strong safeguards before an incident occurs.

8. Remedies and enforcement

Depending on the facts and applicable law, potential consequences of unlawful commercial genomic activity may include:

Regulatory directions or penalties under applicable legislation.

Contractual remedies for breach of enforceable obligations.

Consumer remedies where the statutory requirements are met.

Civil liability for actionable negligence, breach of confidence, or other recognized wrongs.

Patent opposition, revocation, or infringement remedies where the relevant patent-law requirements are satisfied.

Professional or research-ethics consequences for misconduct in clinical or research settings.

These remedies are not interchangeable. A privacy violation does not automatically establish a patent infringement, a right to genomic ownership, or an entitlement to commercial royalties.

9. Critical evaluation

The proposed doctrine seeks to balance two legitimate interests.

Commercial innovation: Genomic research can contribute to earlier diagnosis, precision medicine, drug discovery, and improved understanding of disease.

Individual protection: Individuals should not lose meaningful control over sensitive biological information simply because a commercial organization can derive economic value from it.

Three limitations require particular attention:

Consent alone is insufficient. A consent form cannot excuse inadequate security, misleading representations, or conduct prohibited by law.

Ownership remains legally complex. Physical samples, personal information, inventions, and commercial products are distinct legal objects.

Accountability requires enforceable rules. Ethical recommendations and internal policies are useful, but they do not substitute for legislation, regulatory supervision, and effective remedies.

A sound governance regime should therefore combine informed consent, data protection, scientific integrity, fair commercial practices, and proportionate enforcement.

10. Conclusion

The Commercial Genome Accountability Governance Doctrine is best understood as a proposed framework for regulating the commercial exploitation of human genomic information.

Its principal legal foundations include Puttaswamy for privacy and dignity, Samira Kohli for informed medical consent, Moore for disclosure of commercial interests in biological-material research, Myriad Genetics for limits on patenting naturally occurring genes under US law, and S. and Marper for the privacy implications of retaining DNA information.

Together, these authorities help explain why commercial genomic activity must be evaluated through several distinct legal lenses. They do not establish an automatic right to own one's entire genome as property or to receive a share of every commercial product developed from genetic information.

The central principle is that commercial value derived from human genomic information does not eliminate the legal duties owed to the people whose information is being used.

For a more focused legal study, the next useful step would be to examine this framework specifically under Indian law, with statutory provisions, leading Supreme Court judgments, and the current commencement status of the DPDP regime.